Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs Placebo for Antipsychotic Induced Hyperprolactinemia in Schizophrenia
NCT07386080Phase 4Not yet recruiting
- Sponsor
- Zealand University Hospital
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabergoline in hyperprolactinemia, sponsored by Zealand University Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
cabergoline
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on NCT07386080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386080.